KOREA WHO
-
-
-
CEO of Rznomics
Lee Seong-wook
30-Year RNA Therapy Pioneer, Major Eli Lilly Deal
-
Last Updated on Jan 29, 2026
-
CEO of Rznomics
Life Summary
Lee Seong-wook is the CEO of Rznomics.
He is accelerating the commercialization of the “RNA replacement enzyme platform” and the clinical development of key pipelines.
He was born on February 8, 1963.
He graduated from the Department of Microbiology at Seoul National University and earned a master’s degree in microbiology from Seoul National University Graduate School. He received a Ph.D. in molecular biology from Cornell University in the United States.
He worked as a researcher at Memorial Sloan Kettering Cancer Center and Duke University Medical Center in the United States.
In 1997, he joined Dankook University as a professor of molecular biology. He later served as director of the Nano Sensor Biotech Research Institute within the university and then as director of the Next-Generation Omics Research Institute.
In 2017, he founded Rznomics as a university-affiliated company and has since served concurrently as its CEO.
In May 2025, he drew attention by signing a US$1.3 billion joint research and technology transfer agreement with Eli Lilly for a hereditary hearing loss treatment.
He previously served as president of the Korean Society for Nucleic Acid Research and is currently serving as president of the Korean Society of Gene and Cell Therapy.
#LeeSeongwook #Rznomics #RNAreplacementenzyme #RNAtechnology #biotechnology #geneandcelltherapy #hereditaryhearingloss #EliLilly #omics #Koreanbiotech
He is accelerating the commercialization of the “RNA replacement enzyme platform” and the clinical development of key pipelines.
He was born on February 8, 1963.
He graduated from the Department of Microbiology at Seoul National University and earned a master’s degree in microbiology from Seoul National University Graduate School. He received a Ph.D. in molecular biology from Cornell University in the United States.
He worked as a researcher at Memorial Sloan Kettering Cancer Center and Duke University Medical Center in the United States.
In 1997, he joined Dankook University as a professor of molecular biology. He later served as director of the Nano Sensor Biotech Research Institute within the university and then as director of the Next-Generation Omics Research Institute.
In 2017, he founded Rznomics as a university-affiliated company and has since served concurrently as its CEO.
In May 2025, he drew attention by signing a US$1.3 billion joint research and technology transfer agreement with Eli Lilly for a hereditary hearing loss treatment.
He previously served as president of the Korean Society for Nucleic Acid Research and is currently serving as president of the Korean Society of Gene and Cell Therapy.
#LeeSeongwook #Rznomics #RNAreplacementenzyme #RNAtechnology #biotechnology #geneandcelltherapy #hereditaryhearingloss #EliLilly #omics #Koreanbiotech